Icahn Enterprises IEP Pharma — Inventory Net
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — inventory net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — inventory net?
- Icahn Enterprises (IEP) reported pharma — inventory net of $22M in Q1 2026.
- How has Icahn Enterprises's pharma — inventory net changed year-over-year?
- Icahn Enterprises's pharma — inventory net decreased by 12.0% year-over-year, from $25M to $22M.
- What is the long-term trend for Icahn Enterprises's pharma — inventory net?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — inventory net has grown at a 17.7% compound annual growth rate (CAGR), from $50M to $96M.
- What does pharma — inventory net mean?
- Represents the total value of raw materials, work-in-progress, and finished pharmaceutical products held by the segment. This metric is vital for assessing supply chain efficiency and the segment's ability to meet market demand without overstocking. Effective inventory management is crucial for maintaining margins and avoiding obsolescence in the pharmaceutical sector.